PLUS THERAPEUTICS, Inc. (PSTV): Price and Financial Metrics
PSTV Price/Volume Stats
| Current price | $1.69 | 52-week high | $5.09 |
| Prev. close | $1.67 | 52-week low | $0.97 |
| Day low | $1.60 | Volume | 16,300 |
| Day high | $1.70 | Avg. volume | 30,953 |
| 50-day MA | $1.83 | Dividend yield | N/A |
| 200-day MA | $1.87 | Market Cap | 7.23M |
PSTV Stock Price Chart Interactive Chart >
PLUS THERAPEUTICS, Inc. (PSTV) Company Bio
PLUS THERAPEUTICS, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops, and commercializes specialty novel therapeutics for the treatment of cancer and other life-threatening diseases. PLUS THERAPEUTICS operates in the States of Texas and California.
Latest PSTV News From Around the Web
Below are the latest news stories about PLUS THERAPEUTICS INC that investors may wish to consider to help them evaluate PSTV as an investment opportunity.
Plus Updates Financial and Cash Guidance for 2024Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Pershing Capital to reduce 2024 cash burn by $3.7M AUSTIN, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced financial updates and guidance |
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker AnalysesCollaboration to explore novel CSF cancer testing modalities and initial testing panel to be available in Q1 2024 for ReSPECT-LM patientsAUSTIN, Texas, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it has partnered with K2bio (Houston, Texas) to implement novel analysis for cere |
Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit EuropeAUSTIN, Texas, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Marc H. Hedrick, M.D., President and Chief Executive Officer, will deliver a presentation at the 5th Targeted Radiopharmaceuticals Summit Europe, being held December 5-7, 2023 in Berlin, Germany. 5th Annual Radiopharmaceutic |
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader WebinarMedian overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which is 63% better than current standard of care (bevacizumab monotherapy) of 8 months; 9 of the 15 patients remain alive Median progression free survival (mPFS) is 11 months, compared to SOC at 4 months Rhenium (186Re) Obisbemeda continues to demonstrate a favorable safety profile, despite delivering up to 20x the dose of radiation (up to 740 Gy) typically delivered by external |
Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it will host a virtual KOL event on Monday, November 20, 2023 at 10:00 AM ET to discuss new Phase 2 ReSPECT-GBM data in recurrent glioblastoma presented at the Society for NeuroOncology (SNO) Conference. To register, click here. |
PSTV Price Returns
| 1-mo | N/A |
| 3-mo | -17.96% |
| 6-mo | 31.01% |
| 1-year | -56.63% |
| 3-year | -95.06% |
| 5-year | -99.20% |
| YTD | -3.43% |
| 2023 | -63.19% |
| 2022 | -69.81% |
| 2021 | -48.02% |
| 2020 | -15.83% |
| 2019 | -83.45% |
Loading social stream, please wait...